Entering text into the input field will update the search result below

Momenta oncology drug gets orphan status

Jun. 05, 2014 9:52 AM ETMomenta Pharmaceuticals, Inc. (MNTA) StockBy: Douglas W. House, SA News Editor
  • The FDA designates Momenta Pharmaceuticals' (NASDAQ:MNTA +2.1%) oncology drug candidate necuparanib an Orphan Drug for the treatment of pancreatic cancer. Necuparanib is a heparan sulfate mimetic, derived from unfractionated heparin. It retains its antitumor properties while minimizing its anticoagulant activity.
  • The company expects to complete part A of its Phase 1/2 study of necuparanib in combination with Abraxane and gemcitabine in the next several months. Phase 2 will commence in 2H 2014.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
MNTA--
Momenta Pharmaceuticals, Inc.